Latest & greatest articles for prednisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisone

61. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. (Abstract)

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Circadian rhythms are changed in patients with rheumatoid arthritis. A new modified-release delivery system has been developed which adapts the release of the administered glucocorticoid to the circadian rhythms of endogenous cortisol and disease symptoms to improve the benefit-risk ratio of glucocorticoid (...) therapy in rheumatoid arthritis. We aimed to assess the efficacy and safety of a new modified-release prednisone tablet compared with immediate-release prednisone in patients with this disease.In a 12-week, multicentre, randomised, double-blind trial, 288 patients with active rheumatoid arthritis were randomly assigned to either a modified-release prednisone tablet (n=144) or to an immediate-release prednisone tablet (n=144). The modified-release tablet was taken at bedtime and prednisone was released

2008 Lancet Controlled trial quality: predicted high

62. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. Full Text available with Trip Pro

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy.We randomly assigned 682 patients to receive nine 6-week cycles of melphalan (at a dose of 9 mg (...) per square meter of body-surface area) and prednisone (at a dose of 60 mg per square meter) on days 1 to 4, either alone or with bortezomib (at a dose of 1.3 mg per square meter) on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 4 and on days 1, 8, 22, and 29 during cycles 5 to 9. The primary end point was the time to disease progression.The time to progression among patients receiving bortezomib plus melphalan-prednisone (bortezomib group) was 24.0 months, as compared with 16.6 months

2008 NEJM Controlled trial quality: uncertain

63. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical (...) effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R CRD summary This well-conducted review concluded that docetaxel plus prednisone appears to be the most effective treatment for men with metastatic hormone-refractory prostate cancer. The review was based partially on an indirect comparison of treatments

2007 DARE.

64. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. A systematic review and economic model of the clinical (...) effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Collins R, Fenwick E, Trowman R, Perard R

2007 Health Technology Assessment (HTA) Database.

65. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. (Abstract)

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. In multiple myeloma, combination chemotherapy with melphalan plus prednisone is still regarded as the standard of care in elderly patients. We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve (...) survival.Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT; n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126). The primary endpoint was overall survival. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number

2007 Lancet Controlled trial quality: predicted high

66. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. (Abstract)

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Since 1960, oral melphalan and prednisone (MP) has been regarded as the standard of care in elderly multiple myeloma patients. This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60-85 years.Patients with newly diagnosed multiple myeloma were randomly assigned

2006 Lancet Controlled trial quality: predicted high

67. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma Full Text available with Trip Pro

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment (...) of elderly patients with diffuse large B-cell lymphoma Hornberger J C, Best J H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was compared with rituximab plus

2005 NHS Economic Evaluation Database.

68. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. Full Text available with Trip Pro

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease.From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned (...) of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone); 22 percent, 35 percent (P=0.01), and 31 percent (P=0.08) had predefined reductions in pain; and 13 percent, 22 percent (P=0.009), and 23 percent (P=0.005) had improvements in the quality of life. Adverse events were also more common in the groups that received docetaxel.When given with prednisone, treatment with docetaxel every three weeks led to superior survival

2004 NEJM Controlled trial quality: predicted high

69. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. Full Text available with Trip Pro

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer.We randomly assigned 770 men to one of two treatments, each given in 21-day cycles: 280 mg of estramustine three times (...) daily on days 1 through 5, 60 mg of docetaxel per square meter of body-surface area on day 2, and 60 mg of dexamethasone in three divided doses before docetaxel, or 12 mg of mitoxantrone per square meter on day 1 plus 5 mg of prednisone twice daily. The primary end point was overall survival; secondary end points were progression-free survival, objective response rates, and post-treatment declines of at least 50 percent in serum prostate-specific antigen (PSA) levels.Of 674 eligible patients, 338

2004 NEJM Controlled trial quality: predicted high

70. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma

Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

71. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. Full Text available with Trip Pro

Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. In this randomized, double-blind, placebo-controlled trial, we studied the effectiveness of prednisone in reducing the risk of relapse after outpatient exacerbations of chronic obstructive pulmonary disease (COPD).We enrolled 147 patients who were being discharged from the emergency department after an exacerbation of COPD and randomly assigned them to 10 days of treatment with 40 mg of oral (...) prednisone once daily or identical-appearing placebo. All patients received oral antibiotics for 10 days, plus inhaled bronchodilators. The primary end point was relapse, defined as an unscheduled visit to a physician's office or a return to the emergency department because of worsening dyspnea, within 30 days after randomization.The overall rate of relapse at 30 days was lower in the prednisone group than in the placebo group (27 percent vs. 43 percent, P=0.05), and the time to relapse was prolonged

2003 NEJM Controlled trial quality: predicted high

72. Summaries for patients. Prednisone for rheumatoid arthritis. (Abstract)

Summaries for patients. Prednisone for rheumatoid arthritis. 11777372 2002 01 29 2016 11 24 0003-4819 136 1 2002 Jan 01 Annals of internal medicine Ann. Intern. Med. Summaries for patients. Prednisone for rheumatoid arthritis. I-26 eng Clinical Trial Journal Article Patient Education Handout Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Anti-Inflammatory Agents 0 Glucocorticoids VB0R961HZT Prednisone AIM IM Ann Intern Med. 2002 Jan 1;136(1):1-12 11777359 (...) Administration, Oral Adult Anti-Inflammatory Agents administration & dosage adverse effects Arthritis, Rheumatoid diagnostic imaging drug therapy physiopathology Disease Progression Female Fractures, Bone etiology Glucocorticoids administration & dosage adverse effects Humans Male Middle Aged Osteoporosis chemically induced complications Prednisone administration & dosage adverse effects Radiography 2002 1 5 10 0 2002 1 30 10 1 2002 1 5 10 0 ppublish 11777372 200201010-00002

2002 Annals of Internal Medicine Controlled trial quality: uncertain

73. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. (Abstract)

Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Treatment of adults with autoimmune thrombocytopenic purpura (AITP) is based more on individual experience than on results of controlled studies. We compared intravenous immunoglobulin with high-dose methylprednisolone in untreated adults with severe AITP and assessed efficacy of subsequent oral (...) steroids compared with placebo. Primary outcome was number of days with platelet count greater than 50 x 10(9)/L within the first 21 days.We did a randomised multicentre trial based on a 232 design. 122 adults with severe AITP (platelet count < or =20 x 10(9)/L) were randomly assigned to receive either intravenous immunoglobulin or high-dose methylprednisolone on days 1-3 (randomisation A), and then to receive either oral prednisone or placebo (randomisation B) on days 4-21. Analysis was by intention

2002 Lancet Controlled trial quality: predicted high

74. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma

Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years (...) relative to other cost-utility ratios of other health care interventions. Source of funding Supported by research grants from the Norwegian Cancer Society. Bibliographic details Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. European Journal of Haematology 2001; 66(5): 328-336 PubMedID Other publications of related

2001 NHS Economic Evaluation Database.

75. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma

Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2001 PedsCCM Evidence-Based Journal Club

76. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma.

A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2000 PedsCCM Evidence-Based Journal Club

77. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. (Abstract)

Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. It is uncertain whether the growth impairment that occurs in children during long-term treatment with glucocorticoids persists after the medication is discontinued and ultimately affects adult height.We evaluated growth six to seven years after alternate-day treatment with prednisone had been discontinued in 224 children 6 to 14 years of age with cystic fibrosis who had participated (...) in a multicenter trial of this therapy from 1986 through 1991. Of the children, 151 had been randomly assigned to receive prednisone (either 1 or 2 mg per kilogram of body weight) and 73 to receive placebo. We obtained data on growth up to 1997 from the Cystic Fibrosis Foundation Patient Registry and standardized the data to sex- and age-specific norms from the National Center for Health Statistics. We used z scores to compare growth patterns among treatment groups.In 1997, 68 percent of the patients were 18

2000 NEJM Controlled trial quality: uncertain

78. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. (Abstract)

A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. Inhaled corticosteroids are effective in the treatment of children with asthma. It is uncertain how inhaled corticosteroids compare with oral corticosteroids in the management of severe acute disease.We performed a double-blind, randomized trial involving 100 children five years of age or older who had severe acute asthma (indicated by a forced expiratory volume in one second [FEV1] that was less than (...) 60 percent of the predicted value) and in whom the results could be evaluated. All were treated with an aggressive bronchodilator regimen and received one dose of either 2 mg of inhaled fluticasone through a metered-dose inhaler with a spacer or 2 mg of oral prednisone per kilogram of body weight. They were assessed hourly for up to four hours.The mean (+/-SD) base-line FEV1 as a percentage of the predicted value was 46.3+/-12.5 in the fluticasone group (51 subjects) and 43.9+/-9.9

2000 NEJM Controlled trial quality: uncertain

79. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based (...) mitoxantrone and prednisone (M+P) was compared to prednisone alone (P) in patients with symptomatic hormone-resistant prostate cancer (HRPC). Type of intervention Palliative care. Economic study type Cost-utility analysis. Study population The study population comprised patients with symptomatic HRPC and pain. No further inclusion or exclusion criteria were reported. Setting The setting was tertiary care. The economic study was carried out in Canada. Dates to which data relate The dates during which

1998 NHS Economic Evaluation Database.

80. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha2b in newly diagnosed multiple myeloma: results from a randomised controlled trial

Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha2b in newly diagnosed multiple myeloma: results from a randomised controlled trial Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha2b in newly diagnosed multiple myeloma: results from a randomised controlled trial Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha2b in newly diagnosed multiple myeloma: results from a randomised controlled trial (...) Nord E, Wisloff F, Hjorth M, Westin J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Melphalan plus prednisone with interferon-Alpha2b (MP-IFN) in patients with newly-diagnosed multiple myeloma. Type of intervention Treatment

1997 NHS Economic Evaluation Database.